Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

Jörg Kleef and colleagues systematically reviewed studies on neoadjuvant therapy and tumor response, toxicity, resection, and survival percentages in pancreatic cancer and suggest that patients with locally nonresectable tumors should be included in neoadjuvant protocols.

• Publication year

  2010

• Venue

  PLoS Medicine

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pmed.1000267PMID 20422030PMCID 2857873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: Updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203).

  2016cited by this paper
• Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

  2010cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma.

  2009cited by this paper
• The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials

  2009cited by this paper
• Multivisceral Resection for Pancreatic Malignancies: Risk-Analysis and Long-Term Outcome

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.

  2008cited by this paper
• Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress

  2008cited by this paper
• Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial

  2008cited by this paper
• Most Pancreatic Cancer Resections are R1 Resections

  2008cited by this paper
• Neoadjuvant Therapy for Pancreatic Cancer

  2008cited by this paper
• Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

  2008cited by this paper
• Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses

  2008cited by this paper
• Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

  2007cited by this paper
• Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO

  2007cited by this paper
• Surgery for Recurrent Pancreatic Ductal Adenocarcinoma

  2007cited by this paper
• Systematic review and meta‐analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer

  2007cited by this paper
• National Failure to Operate on Early Stage Pancreatic Cancer

  2007cited by this paper
• [S3-Guidelines "Exocrine pancreatic cancer" 2007].

  2007cited by this paper
• Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

  2007cited by this paper
• Neoadjuvant therapy for pancreatic cancer

  2007cited by this paper
• Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.

  2007cited by this paper
• Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma

  2006cited by this paper
• Redefining the R1 resection in pancreatic cancer

  2006cited by this paper
• Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer

  2006cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005influential reference
• Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.

  2005cited by this paper
• Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer

  2004cited by this paper
• An evaluation of the Vincentizing method of forming group-level response time distributions

  2004cited by this paper
• A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

  2004cited by this paper
• Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy.

  2003cited by this paper
• Combined modality therapy for pancreatic cancer.

  2003cited by this paper
• Hospital volume and surgical mortality in the United States.

  2002cited by this paper
• Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

  2002cited by this paper
• Evidence-Based Pancreatic Head Resection for Pancreatic Cancer and Chronic Pancreatitis

  2002cited by this paper
• Cancer Research UK

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

  1999cited by this paper
• Controversies in meta-analysis: the case of the trials of serum cholesterol reduction

  1993cited by this paper
• Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.

  1993cited by this paper
• Preoperative staging and assessment of resectability of pancreatic cancer.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer

  1987cited by this paper
• Multimodality therapy of localized unresectable pancreatic adenocarcinoma

  1984cited by this paper
• Preoperative irradiation in carcinoma of the pancreas

  1980cited by this paper
• The Inverse of the Freeman – Tukey Double Arcsine Transformation

  1978cited by this paper
• Transformations Related to the Angular and the Square Root

  1950cited by this paper

• Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

  2026cites this paper
• Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment.

  2026cites this paper
• Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer

  2026cites this paper
• Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

  2026cites this paper
• Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic ductal adenocarcinoma: a retrospective propensity score-matched cohort study

  2025cites this paper
• Identification and validation of BCL11A as a neural and immune vulnerability factor in pancreatic adenocarcinoma.

  2025cites this paper
• Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single‐Center Retrospective Study

  2025cites this paper
• Comprehensive insights into pancreatic cancer treatment approaches and cutting-edge nanocarrier solutions: from pathology to nanomedicine

  2025cites this paper
• Current oncological management options for hepato-pancreato-biliary cancers

  2025cites this paper
• Design and Evaluation of RNA Aptamer–Mediated Delivery of C/EBPβ siRNA for Oncological Therapy

  2025cites this paper
• TRIM21 as a potential prognostic biomarker and therapeutic target affects the growth of pancreatic cancer

  2025cites this paper
• Cytology and Core Biopsy for Cystic Lesions of the Pancreas: A Comparison of Three Cytological Grading Systems

  2025cites this paper
• Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer

  2025cites this paper
• Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer

  2025cites this paper
• Honokiol modulates invasion and autophagy in pancreatic cancer via the miR-101/QKI axis in cancer-associated fibroblasts

  2025cites this paper
• Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic cancer—insights from an in silico study

  2025cites this paper
• Common Hepatic Artery Resection and Reconstruction During Pancreaticoduodenectomy Following Chemotherapy for Locally-Advanced Pancreatic Cancer: A Case Report

  2025cites this paper
• Tumor-to-anterior pancreas surface distance on CT: a potential preoperative predictor of resection margin status in pancreatic body and tail adenocarcinoma.

  2025cites this paper
• A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery

  2025cites this paper
• Metastatic pancreatic cancer now in remission: a case report and literature review

  2025cites this paper
• The Role of IL‐6, IL‐10 and CRP in Gastrointestinal Cancers

  2025cites this paper
• A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer.

  2025cites this paper
• Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer

  2025cites this paper
• Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study)

  2025cites this paper
• Nanoparticle-induced toxicity in pancreatic cancer: Insights from machine learning models

  2025cites this paper
• Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

  2025cites this paper
• Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge

  2025cites this paper
• Efficacy of irreversible electroporation combined with immunotherapy versus irreversible electroporation alone in locally advanced pancreatic cancer: a propensity score-matched retrospective study

  2025cites this paper
• Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy.

  2025cites this paper
• Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer

  2025cites this paper
• Chalcomoracin induces autophagy-mediated apoptosis in pancreatic cancer by suppressing the mTOR pathway

  2025cites this paper
• Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies

  2025cites this paper
• Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma: Aligning Guideline Recommendations with Real-World Evidence

  2025cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer

  2025cites this paper
• A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

  2025cites this paper
• Research progress on perioperative prediction models for postoperative pancreatic fistula after pancreatic tumor surgery.

  2025cites this paper
• Complete Pathological Response to Neoadjuvant Treatment in Pancreatic Ductal Adenocarcinoma—Can We Achieve a Long-Term Survival? A Narrative Review

  2025cites this paper
• Therapeutic Efficacy of Neoadjuvant Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A Meta-analysis.

  2025cites this paper
• Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis

  2025cites this paper
• Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy

  2025cites this paper
• Moving from the background towards the spotlight: A critical review of radiation therapy for locally advanced pancreas cancer.

  2025cites this paper
• New insights into disease dynamics and treatment interventions with PID controller-based therapeutic strategies for pancreatic cancer

  2025cites this paper
• TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

  2025cites this paper
• The Relationship of the Microbiome, Associated Metabolites and the Gut Barrier with Pancreatic Cancer.

  2025cites this paper
• Oncogenic Peptide Encoded by Noncoding RNA of FOXM1 Promotes Pancreatic Cancer Malignancy Through PI3K/AKT Signaling

  2025cites this paper
• Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature

  2025cites this paper
• Anticancer Activity of Maitake D-Fraction (PDF) against Three Highly Aggressive Cancer Cells

  2025cites this paper
• Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma—A Multicentre Propensity Score Matching Analysis of the Recurrence After Whipple’s (RAW) Study

  2025cites this paper
• Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis.

  2025cites this paper
• A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer

  2025cites this paper
• Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy

  2025cites this paper
• To Predict the Prognosis and Immunological Characteristics of Pancreatic Cancer Based on Disulfide-Death Gene Death-Related lncRNA

  2025cites this paper
• Dual Role of NRF2 in Pancreatic Precursor Lesions

  2025cites this paper
• Evaluation of pancreatic cancer specimens for comprehensive genomic profiling

  2024cites this paper
• Construction and validation of a nomogram for cancer specific survival of postoperative pancreatic cancer based on the SEER and China database

  2024cites this paper
• Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

  2024cites this paper
• Risk factors of post-operative diarrhoea in patients with pancreatic cancer after neoadjuvant chemotherapy: A retrospective cohort study.

  2024cites this paper
• New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.

  2024cites this paper
• Is it resectable? A survey regarding tumor classification and vascular involvement.

  2024cites this paper
• The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

  2024cites this paper
• Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

  2024cites this paper
• The scheme, and regulative mechanism of pyroptosis, ferroptosis, and necroptosis in radiation injury

  2024cites this paper
• Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials

  2024cites this paper
• TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.

  2024cites this paper
• Epigenetic therapeutic strategies in pancreatic cancer.

  2024cites this paper
• Neoadjuvant chemo‐ or chemo‐radiation‐therapy of pancreatic ductal adenocarcinoma differentially shift ECM composition, complement activation, energy metabolism and ribosomal proteins of the residual tumor mass

  2024influential citation
• Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation.

  2024cites this paper
• PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa‐2 cells via the inhibitions of p‐Akt/mTOR/NF‐κB and MMP2/MMP9 signaling pathways in vitro

  2024cites this paper
• Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts

  2024cites this paper
• The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies

  2024cites this paper
• Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth

  2024cites this paper
• Ablation alone is noninferior to radiotherapy plus ablation in the patients with early-stage hepatocellular carcinoma: a population-based study

  2024cites this paper
• Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study

  2024cites this paper
• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• Risk factors for postoperative complications following pancreatic resections – a single-center observational study

  2024cites this paper
• A prospective randomized control study of neo-adjuvant chemo radiation followed by surgery versus upfront surgery in resectable and borderline resectable pancreatic head cancer: Pilot study

  2024cites this paper
• Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study

  2024cites this paper
• The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma

  2024cites this paper
• Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care

  2024cites this paper
• Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) for Pancreatic Adenocarcinoma: A Review

  2024cites this paper
• Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis

  2024cites this paper
• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• Curcumin-loaded emulsome nanoparticles induces apoptosis through p53 signaling pathway in pancreatic cancer cell line PANC-1.

  2024cites this paper
• Thrombosis and anticoagulation after portal vein reconstruction during pancreatic surgery - A systematic review.

  2024cites this paper
• Prediction of R0 Resectability in Pancreatic Adenocarcinoma by MRI Using NCCN Criteria

  2024cites this paper
• Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice

  2024cites this paper
• Role of Endoscopic Ultrasound-Guided Radiofrequency Ablation in Pancreatic Lesions: Where Are We Now and What Does the Future Hold?

  2024cites this paper
• Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Prognostic impact of the CALLY index in patients with resectable pancreatic cancer

  2024cites this paper
• Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report

  2024cites this paper
• Cytologic testing for mismatch repair deficiency/microsatellite instability and NTRK gene fusion is not routinely indicated in primary pancreaticobiliary carcinoma cell block material.

  2024cites this paper
• The effect of longer epidural duration after open pancreaticoduodenectomy on pain and mobilisation: A retrospective single-centre analysis

  2024cites this paper
• Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study

  2024cites this paper
• Micronutrients Importance in Cancer Prevention-Vitamins.

  2024cites this paper
• Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

  2024cites this paper
• Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation

  2024cites this paper
• Trends in the treatment of advanced pancreatic cancer.

  2024cites this paper
• Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analysis

  2024cites this paper
• Impact of Irreversible Electroporation on Survival Among Patients with Borderline Resectable/Locally Advanced Pancreatic Cancer: A Single Center Experience

  2024cites this paper